All trades / TUSK
TUSK
MAMMOTH ENERGY SERVICES, INC.
70Open-market trades
+32.1%Avg 90d after buys
+6.22%Avg 90d after sales
+74.4%Avg 180d after buys
Price and insider prints
TUSK adjusted close▲ buy▼ sale
Trades
| Date | Form 4 | Ticker | Insider | Title | Side | Shares | Value | 90d | 180d |
|---|---|---|---|---|---|---|---|---|---|
| 9/16/2026 | Form 4 | TUSK | Plaumann Mark LawrenceMark Plaumann, age 70, has served as one of our directors since June 2025. Mr. Plaumann is currently a Managing Member of Greyhawke Capital Advisors LLC, or Greyhawke, which he co-founded in 1998. Prior to founding Greyhawke, Mr. Plaumann was a Senior Vice President of Wexford Capital LP. Mr. Plaumann was formerly a Managing Director of Alvarez & Marsal, Inc. and the President of American Healthcare Management, Inc. He also was Senior Manager at Ernst & Young LLP. Mr. Plaumann served as a director and audit committee chairman for ICx Technologies, Inc. from 2006 until 2010, served as a director and a member of the audit and compensation committees of Republic Airways Holdings, Inc. from 2002 until 2017 and… | Director | BUY | 5,000 | $15.0K | +3.66%hist | +7.30%hist |
| 6/17/2026 | Form 4 | TUSK | DAVIDSON CHARLES E · JACOBS JOSEPH · WEXFORD CAPITAL LP · Wexford GP LLC | Chief Business Officer | BUY | 4,019,574 | $10.45M | 0.00% | +4.01%hist |
| 6/12/2026 | Form 4 | TUSK | Amron Arthur HMr. Amron has served on the board of directors of Nephros, Inc., a public commercial stage medical device company, since September 2007. From 1991 to 1994, Mr. Amron was an Associate at Schulte Roth & Zabel LLP, specializing in corporate and bankruptcy law and, from 1984 to 1991, Mr. Amron was an Associate at Debevoise & Plimpton LLP specializing in corporate litigation and bankruptcy law. Mr. Amron holds a J.D. from Harvard University and a B.A. in Political Theory from Colgate University and is an inactive member of the New York Bar. We believe Mr. Amron’s legal training and extensive transactional experience, including in mergers and acquisitions, private equity investments and financing transactions, as… | Director | BUY | 2,000 | $6.6K | −5.47% | −0.89%hist |
| 6/11/2026 | Form 4 | TUSK | Amron Arthur HMr. Amron has served on the board of directors of Nephros, Inc., a public commercial stage medical device company, since September 2007. From 1991 to 1994, Mr. Amron was an Associate at Schulte Roth & Zabel LLP, specializing in corporate and bankruptcy law and, from 1984 to 1991, Mr. Amron was an Associate at Debevoise & Plimpton LLP specializing in corporate litigation and bankruptcy law. Mr. Amron holds a J.D. from Harvard University and a B.A. in Political Theory from Colgate University and is an inactive member of the New York Bar. We believe Mr. Amron’s legal training and extensive transactional experience, including in mergers and acquisitions, private equity investments and financing transactions, as… | Director | BUY | 2,500 | $8.1K | −0.63% | −0.89%hist |
| 5/28/2026 | Form 4 | TUSK | Amron Arthur HMr. Amron has served on the board of directors of Nephros, Inc., a public commercial stage medical device company, since September 2007. From 1991 to 1994, Mr. Amron was an Associate at Schulte Roth & Zabel LLP, specializing in corporate and bankruptcy law and, from 1984 to 1991, Mr. Amron was an Associate at Debevoise & Plimpton LLP specializing in corporate litigation and bankruptcy law. Mr. Amron holds a J.D. from Harvard University and a B.A. in Political Theory from Colgate University and is an inactive member of the New York Bar. We believe Mr. Amron’s legal training and extensive transactional experience, including in mergers and acquisitions, private equity investments and financing transactions, as… | Director | BUY | 3,000 | $9.8K | −2.18% | −0.89%hist |
| 5/26/2026 | Form 4 | TUSK | Amron Arthur HMr. Amron has served on the board of directors of Nephros, Inc., a public commercial stage medical device company, since September 2007. From 1991 to 1994, Mr. Amron was an Associate at Schulte Roth & Zabel LLP, specializing in corporate and bankruptcy law and, from 1984 to 1991, Mr. Amron was an Associate at Debevoise & Plimpton LLP specializing in corporate litigation and bankruptcy law. Mr. Amron holds a J.D. from Harvard University and a B.A. in Political Theory from Colgate University and is an inactive member of the New York Bar. We believe Mr. Amron’s legal training and extensive transactional experience, including in mergers and acquisitions, private equity investments and financing transactions, as… | Director | BUY | 2,500 | $8.1K | −3.72% | −0.89%hist |
| 12/11/2025 | Form 4 | TUSK | Amron Arthur HMr. Amron has served on the board of directors of Nephros, Inc., a public commercial stage medical device company, since September 2007. From 1991 to 1994, Mr. Amron was an Associate at Schulte Roth & Zabel LLP, specializing in corporate and bankruptcy law and, from 1984 to 1991, Mr. Amron was an Associate at Debevoise & Plimpton LLP specializing in corporate litigation and bankruptcy law. Mr. Amron holds a J.D. from Harvard University and a B.A. in Political Theory from Colgate University and is an inactive member of the New York Bar. We believe Mr. Amron’s legal training and extensive transactional experience, including in mergers and acquisitions, private equity investments and financing transactions, as… | Director | BUY | 10,000 | $18.9K | +18.3% | +79.6% |
| 5/22/2025 | Form 4 | TUSK | SMITH ARTHUR L | Director | SELL | 20,000 | $50.2K | +10.7% | +27.5% |
| 5/20/2025 | Form 4 | TUSK | SMITH ARTHUR L | Director | SELL | 50,000 | $125.5K | +4.90% | +24.5% |
| 5/19/2025 | Form 4 | TUSK | SMITH ARTHUR L | Director | SELL | 15,000 | $37.4K | +6.80% | +26.0% |
| 12/12/2024 | Form 4 | TUSK | Amron Arthur HMr. Amron has served on the board of directors of Nephros, Inc., a public commercial stage medical device company, since September 2007. From 1991 to 1994, Mr. Amron was an Associate at Schulte Roth & Zabel LLP, specializing in corporate and bankruptcy law and, from 1984 to 1991, Mr. Amron was an Associate at Debevoise & Plimpton LLP specializing in corporate litigation and bankruptcy law. Mr. Amron holds a J.D. from Harvard University and a B.A. in Political Theory from Colgate University and is an inactive member of the New York Bar. We believe Mr. Amron’s legal training and extensive transactional experience, including in mergers and acquisitions, private equity investments and financing transactions, as… | Director | BUY | 1,000 | $3.0K | −28.3% | 0.00% |
| 11/25/2024 | Form 4 | TUSK | Booker Corey J.Corey Booker, age 50, has served as a director of the Company since August 2020. Dr. Booker is the founder, and since November 2012 has served as the Chief Executive Officer, of Bedside LLC (formerly OnPulse, LLC), a healthcare management services company designed to improve patient health through advocacy, care coordination, communication and increased patient health literacy. In addition to his career at Bedside LLC, Dr. Booker practiced medicine as a maternal fetal specialist at Duke University Hospital from October 2012 to June 2017. Dr. Booker has served on the board of directors of HarborPath Inc., or HarborPath, a non-profit patient assistance program providing specialty pharmacy gap coverage to… | Director | SELL | 15,000 | $52.0K | +27.5% | +26.6% |
| 11/22/2024 | Form 4 | TUSK | Booker Corey J.Corey Booker, age 50, has served as a director of the Company since August 2020. Dr. Booker is the founder, and since November 2012 has served as the Chief Executive Officer, of Bedside LLC (formerly OnPulse, LLC), a healthcare management services company designed to improve patient health through advocacy, care coordination, communication and increased patient health literacy. In addition to his career at Bedside LLC, Dr. Booker practiced medicine as a maternal fetal specialist at Duke University Hospital from October 2012 to June 2017. Dr. Booker has served on the board of directors of HarborPath Inc., or HarborPath, a non-profit patient assistance program providing specialty pharmacy gap coverage to… | Director | SELL | 10,000 | $34.3K | +19.2% | +30.1% |
| 11/21/2024 | Form 4 | TUSK | Booker Corey J.Corey Booker, age 50, has served as a director of the Company since August 2020. Dr. Booker is the founder, and since November 2012 has served as the Chief Executive Officer, of Bedside LLC (formerly OnPulse, LLC), a healthcare management services company designed to improve patient health through advocacy, care coordination, communication and increased patient health literacy. In addition to his career at Bedside LLC, Dr. Booker practiced medicine as a maternal fetal specialist at Duke University Hospital from October 2012 to June 2017. Dr. Booker has served on the board of directors of HarborPath Inc., or HarborPath, a non-profit patient assistance program providing specialty pharmacy gap coverage to… | Director | SELL | 6,709 | $21.8K | +14.6% | +24.1% |
| 11/20/2024 | Form 4 | TUSK | Booker Corey J.Corey Booker, age 50, has served as a director of the Company since August 2020. Dr. Booker is the founder, and since November 2012 has served as the Chief Executive Officer, of Bedside LLC (formerly OnPulse, LLC), a healthcare management services company designed to improve patient health through advocacy, care coordination, communication and increased patient health literacy. In addition to his career at Bedside LLC, Dr. Booker practiced medicine as a maternal fetal specialist at Duke University Hospital from October 2012 to June 2017. Dr. Booker has served on the board of directors of HarborPath Inc., or HarborPath, a non-profit patient assistance program providing specialty pharmacy gap coverage to… | Director | SELL | 5,000 | $16.1K | +11.5% | +22.6% |
| 11/14/2024 | Form 4 | TUSK | Booker Corey J.Corey Booker, age 50, has served as a director of the Company since August 2020. Dr. Booker is the founder, and since November 2012 has served as the Chief Executive Officer, of Bedside LLC (formerly OnPulse, LLC), a healthcare management services company designed to improve patient health through advocacy, care coordination, communication and increased patient health literacy. In addition to his career at Bedside LLC, Dr. Booker practiced medicine as a maternal fetal specialist at Duke University Hospital from October 2012 to June 2017. Dr. Booker has served on the board of directors of HarborPath Inc., or HarborPath, a non-profit patient assistance program providing specialty pharmacy gap coverage to… | Director | SELL | 3,607 | $12.6K | +18.0% | +25.5% |
| 11/13/2024 | Form 4 | TUSK | Booker Corey J.Corey Booker, age 50, has served as a director of the Company since August 2020. Dr. Booker is the founder, and since November 2012 has served as the Chief Executive Officer, of Bedside LLC (formerly OnPulse, LLC), a healthcare management services company designed to improve patient health through advocacy, care coordination, communication and increased patient health literacy. In addition to his career at Bedside LLC, Dr. Booker practiced medicine as a maternal fetal specialist at Duke University Hospital from October 2012 to June 2017. Dr. Booker has served on the board of directors of HarborPath Inc., or HarborPath, a non-profit patient assistance program providing specialty pharmacy gap coverage to… | Director | SELL | 7,100 | $26.1K | +15.7% | +27.9% |
| 11/11/2024 | Form 4 | TUSK | Booker Corey J.Corey Booker, age 50, has served as a director of the Company since August 2020. Dr. Booker is the founder, and since November 2012 has served as the Chief Executive Officer, of Bedside LLC (formerly OnPulse, LLC), a healthcare management services company designed to improve patient health through advocacy, care coordination, communication and increased patient health literacy. In addition to his career at Bedside LLC, Dr. Booker practiced medicine as a maternal fetal specialist at Duke University Hospital from October 2012 to June 2017. Dr. Booker has served on the board of directors of HarborPath Inc., or HarborPath, a non-profit patient assistance program providing specialty pharmacy gap coverage to… | Director | SELL | 3,494 | $12.6K | +16.8% | +29.1% |
| 11/8/2024 | Form 4 | TUSK | Booker Corey J.Corey Booker, age 50, has served as a director of the Company since August 2020. Dr. Booker is the founder, and since November 2012 has served as the Chief Executive Officer, of Bedside LLC (formerly OnPulse, LLC), a healthcare management services company designed to improve patient health through advocacy, care coordination, communication and increased patient health literacy. In addition to his career at Bedside LLC, Dr. Booker practiced medicine as a maternal fetal specialist at Duke University Hospital from October 2012 to June 2017. Dr. Booker has served on the board of directors of HarborPath Inc., or HarborPath, a non-profit patient assistance program providing specialty pharmacy gap coverage to… | Director | SELL | 24 | $90.24 | +14.9% | +30.7% |
| 11/7/2024 | Form 4 | TUSK | Booker Corey J.Corey Booker, age 50, has served as a director of the Company since August 2020. Dr. Booker is the founder, and since November 2012 has served as the Chief Executive Officer, of Bedside LLC (formerly OnPulse, LLC), a healthcare management services company designed to improve patient health through advocacy, care coordination, communication and increased patient health literacy. In addition to his career at Bedside LLC, Dr. Booker practiced medicine as a maternal fetal specialist at Duke University Hospital from October 2012 to June 2017. Dr. Booker has served on the board of directors of HarborPath Inc., or HarborPath, a non-profit patient assistance program providing specialty pharmacy gap coverage to… | Director | SELL | 165 | $643.50 | +17.4% | +29.8% |
| 5/30/2024 | Form 4 | TUSK | Amron Arthur HMr. Amron has served on the board of directors of Nephros, Inc., a public commercial stage medical device company, since September 2007. From 1991 to 1994, Mr. Amron was an Associate at Schulte Roth & Zabel LLP, specializing in corporate and bankruptcy law and, from 1984 to 1991, Mr. Amron was an Associate at Debevoise & Plimpton LLP specializing in corporate litigation and bankruptcy law. Mr. Amron holds a J.D. from Harvard University and a B.A. in Political Theory from Colgate University and is an inactive member of the New York Bar. We believe Mr. Amron’s legal training and extensive transactional experience, including in mergers and acquisitions, private equity investments and financing transactions, as… | Director | BUY | 3,000 | $10.9K | +2.16% | −1.08% |
| 5/28/2024 | Form 4 | TUSK | Amron Arthur HMr. Amron has served on the board of directors of Nephros, Inc., a public commercial stage medical device company, since September 2007. From 1991 to 1994, Mr. Amron was an Associate at Schulte Roth & Zabel LLP, specializing in corporate and bankruptcy law and, from 1984 to 1991, Mr. Amron was an Associate at Debevoise & Plimpton LLP specializing in corporate litigation and bankruptcy law. Mr. Amron holds a J.D. from Harvard University and a B.A. in Political Theory from Colgate University and is an inactive member of the New York Bar. We believe Mr. Amron’s legal training and extensive transactional experience, including in mergers and acquisitions, private equity investments and financing transactions, as… | Director | BUY | 2,000 | $7.1K | +3.00% | −6.81% |
| 3/12/2024 | Form 4 | TUSK | Amron Arthur HMr. Amron has served on the board of directors of Nephros, Inc., a public commercial stage medical device company, since September 2007. From 1991 to 1994, Mr. Amron was an Associate at Schulte Roth & Zabel LLP, specializing in corporate and bankruptcy law and, from 1984 to 1991, Mr. Amron was an Associate at Debevoise & Plimpton LLP specializing in corporate litigation and bankruptcy law. Mr. Amron holds a J.D. from Harvard University and a B.A. in Political Theory from Colgate University and is an inactive member of the New York Bar. We believe Mr. Amron’s legal training and extensive transactional experience, including in mergers and acquisitions, private equity investments and financing transactions, as… | Director | BUY | 3,000 | $11.2K | −1.64% | −1.10% |
| 12/19/2023 | Form 4 | TUSK | Straehla Arty | Chief Executive Officer | SELL | 40,000 | $174.0K | +19.2% | +26.7% |
| 12/18/2023 | Form 4 | TUSK | Straehla Arty | Chief Executive Officer | SELL | 30,000 | $131.4K | +17.5% | +25.2% |
| 12/15/2023 | Form 4 | TUSK | Straehla Arty | Chief Executive Officer | SELL | 40,000 | $174.4K | +17.8% | +16.9% |
| 12/14/2023 | Form 4 | TUSK | Straehla Arty | Chief Executive Officer | SELL | 55,000 | $244.2K | +18.9% | +19.2% |
| 12/13/2023 | Form 4 | TUSK | Straehla Arty | Chief Executive Officer | SELL | 25,000 | $109.7K | +20.7% | +22.0% |
| 11/11/2022 | Form 4 | TUSK | SMITH ARTHUR L | Director | SELL | 20,000 | $141.4K | +14.4% | +49.4% |
| 6/17/2022 | Form 4 | TUSK | DAVIDSON CHARLES E · JACOBS JOSEPH · WEXFORD CAPITAL LP · Wexford GP LLC | 10% owner and Director | BUY | 10,382 | $22.5K | +99.5% | +190.4% |
| 6/16/2022 | Form 4 | TUSK | DAVIDSON CHARLES E · JACOBS JOSEPH · WEXFORD CAPITAL LP · Wexford GP LLC | 10% owner and Director | BUY | 35,000 | $74.5K | +110.9% | +178.7% |
| 6/15/2022 | Form 4 | TUSK | DAVIDSON CHARLES E · JACOBS JOSEPH · WEXFORD CAPITAL LP · Wexford GP LLC | 10% owner and Director | BUY | 5,100 | $11.4K | +102.7% | +158.5% |
| 6/14/2022 | Form 4 | TUSK | DAVIDSON CHARLES E · JACOBS JOSEPH · WEXFORD CAPITAL LP · Wexford GP LLC | 10% owner and Director | BUY | 20,600 | $47.0K | +105.3% | +156.2% |
| 6/13/2022 | Form 4 | TUSK | DAVIDSON CHARLES E · JACOBS JOSEPH · WEXFORD CAPITAL LP · Wexford GP LLC | 10% owner and Director | BUY | 25,102 | $59.0K | +100.9% | +150.6% |
| 6/10/2022 | Form 4 | TUSK | DAVIDSON CHARLES E · JACOBS JOSEPH · WEXFORD CAPITAL LP · Wexford GP LLC | 10% owner and Director | BUY | 54,779 | $134.8K | +78.0% | +126.0% |
| 6/9/2022 | Form 4 | TUSK | DAVIDSON CHARLES E · JACOBS JOSEPH · WEXFORD CAPITAL LP · Wexford GP LLC | 10% owner and Director | BUY | 27,489 | $68.2K | +85.0% | +123.6% |
| 6/8/2022 | Form 4 | TUSK | DAVIDSON CHARLES E · JACOBS JOSEPH · WEXFORD CAPITAL LP · Wexford GP LLC | 10% owner and Director | BUY | 15,500 | $38.8K | +73.5% | +119.1% |
| 3/10/2022 | Form 4 | TUSK | Layton Mark E. | CFO and Secretary | SELL | 40,417 | $82.5K | −27.9% | −121.9% |
| 12/13/2021 | Form 4 | TUSK | SMITH ARTHUR L | Director | BUY | 25,000 | $50.0K | +8.02% | +23.5% |
| 3/11/2021 | Form 4 | TUSK | Layton Mark E. | CFO and Secretary | SELL | 55,789 | $291.2K | +26.5% | +30.3% |
| 3/10/2021 | Form 4 | TUSK | Straehla Arty | Chief Executive Officer | SELL | 102,435 | $541.9K | +30.6% | +33.5% |
| 3/9/2021 | Form 4 | TUSK | Straehla Arty | Chief Executive Officer | SELL | 46,555 | $254.7K | +27.5% | +32.7% |
| 11/10/2020 | Form 4 | TUSK | Straehla Arty | Chief Executive Officer | SELL | 5,000 | $8.9K | −165.0% | −102.8% |
| 9/4/2020 | Form 4 | TUSK | SMITH ARTHUR L | Director | BUY | 20,000 | $25.8K | +65.9% | +337.0% |
| 11/21/2019 | Form 4 | TUSK | Ross Matthew | Director | SELL | 2,913 | $4.2K | +0.69% | +12.4% |
| 11/20/2019 | Form 4 | TUSK | DAVIDSON CHARLES E · JACOBS JOSEPH · MEH SUB LLC · WEXFORD CAPITAL LP · Wexford Catalyst Trading LTD · Wexford GP LLC · Wexford Spectrum Trading LTD | 10% owner and Director | BUY | 16,692 | $22.2K | −8.67% | −20.0% |
| 11/13/2019 | Form 4 | TUSK | DAVIDSON CHARLES E · JACOBS JOSEPH · MEH SUB LLC · WEXFORD CAPITAL LP · Wexford Catalyst Trading LTD · Wexford GP LLC · Wexford Spectrum Trading LTD | 10% owner and Director | BUY | 35,904 | $48.8K | −0.72% | −6.52% |
| 12/3/2018 | Form 4 | TUSK | SMITH ARTHUR L | Director | SELL | 6,000 | $149.1K | +8.77% | +57.1% |
| 11/12/2018 | Form 4 | TUSK | Straehla Arty | Chief Executive Officer | SELL | 2,230 | $58.4K | +15.8% | +43.9% |
| 11/9/2018 | Form 4 | TUSK | Layton Mark E. | CFO and Secretary | SELL | 142 | $3.7K | +19.6% | +45.1% |
| 11/8/2018 | Form 4 | TUSK | Layton Mark E. | CFO and Secretary | SELL | 994 | $27.1K | +16.5% | +45.7% |
| 11/8/2018 | Form 4 | TUSK | Straehla Arty | Chief Executive Officer | SELL | 11,460 | $312.7K | +16.5% | +45.7% |
| 11/8/2018 | Form 4 | TUSK | Straehla Arty | Chief Executive Officer | SELL | 25,151 | $665.2K | +16.5% | +45.7% |
| 7/30/2018 | Form 4 | TUSK | DAVIDSON CHARLES E · JACOBS JOSEPH · MEH SUB LLC · WEXFORD CAPITAL LP · Wexford GP LLC | 10% owner and Director | SELL | 266,026 | $10.11M | +31.6% | +35.7% |
| 7/30/2018 | Form 4 | TUSK | GULFPORT ENERGY CORP | 10% owner and Director | SELL | 118,974 | $4.52M | +31.6% | +35.7% |
| 6/29/2018 | Form 4 | TUSK | DAVIDSON CHARLES E · JACOBS JOSEPH · MEH SUB LLC · WEXFORD CAPITAL LP · Wexford GP LLC | 10% owner and Director | SELL | 2,764,400 | $105.07M | +15.3% | +46.1% |
| 6/29/2018 | Form 4 | TUSK | GULFPORT ENERGY CORP | 10% owner and Director | SELL | 1,235,600 | $46.97M | +15.3% | +46.1% |
| 3/1/2018 | Form 4 | TUSK | Layton Mark E. | CFO and Secretary | SELL | 4,373 | $114.3K | −42.0% | −12.6% |
| 11/15/2017 | Form 4 | TUSK | Straehla Arty | Chief Executive Officer | SELL | 7,553 | $134.5K | −12.6% | −90.3% |
| 11/14/2017 | Form 4 | TUSK | Layton Mark E. | CFO and Secretary | SELL | 925 | $17.6K | −8.57% | −81.7% |
| 11/14/2017 | Form 4 | TUSK | Straehla Arty | Chief Executive Officer | SELL | 18,289 | $342.2K | −8.57% | −81.7% |
| 8/25/2017 | Form 4 | TUSK | Palm James D | Director | BUY | 2,000 | $25.2K | +47.2% | +56.4% |
| 8/24/2017 | Form 4 | TUSK | Palm James D | Director | BUY | 4,000 | $51.3K | +47.0% | +56.7% |
| 6/9/2017 | Form 4 | TUSK | SMITH ARTHUR L | Director | BUY | 6,000 | $101.5K | −18.7% | +0.41% |
| 2/28/2017 | Form 4 | TUSK | Straehla Arty | Chief Executive Officer | BUY | 460 | $10.0K | −14.6% | −40.5% |
| 10/19/2016 | Form 4 | TUSK | DAVIDSON CHARLES E · JACOBS JOSEPH · Mammoth Energy Holdings LLC · WEXFORD CAPITAL LP · Wexford GP LLC | 10% owner and Director | SELL | 171,797 | $2.42M | −22.5% | −34.6% |
| 10/19/2016 | Form 4 | TUSK | Straehla Arty | Chief Executive Officer | BUY | 666 | $10.0K | +22.5% | +34.6% |
| 10/19/2016 | Form 4 | TUSK | Straehla Arty | Chief Executive Officer | BUY | 666 | $10.0K | +22.5% | +34.6% |
| 10/19/2016 | Form 4 | TUSK | Layton Mark E. | CFO and Secretary | BUY | 3,000 | $45.0K | +22.5% | +34.6% |
| 10/19/2016 | Form 4 | TUSK | GULFPORT ENERGY CORP | 10% owner and Director | SELL | 76,250 | $1.07M | −22.5% | −34.6% |
Chart shows split-adjusted close for the last three years, or the selected date range. Triangles mark open-market Form 4 purchases and sales in that window.